In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Gets Its First Biosimilar Approval

This article was originally published in Scrip

Executive Summary

Within just three and a half years since its establishment, Samsung Bioepis has received its first regulatory approval for a biosimilar, meaning the Samsung Group affiliate is now set to release its version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) in South Korea late this year or early next. It will be the fourth locally developed biosimilar to hit the domestic market and is expected to be priced at about a 30% discount.

You may also be interested in...



CrystalGenomics Eyes COVID-19 Trials As Hopes Rise For Ivaltinostat

Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.

Korean CROs Narrow Gap But Seek Continued State Support

A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.

Celltrion Pledges Efforts on Coronavirus Antibody And Kit

Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel